Beam Therapeutics Inc. (BEAM) Announces the Participation in Chardan Virtual 4th Annual Genetic Medicines Conference

Beam Therapeutics Inc. (BEAM) today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. ET.

On September 29, 2020, Beam Therapeutics Inc. (BEAM) reported the beginning of a proposed public offering of 4,500,000 shares of its common stock. All of the shares will be offered by Beam. Beam also anticipates to grant the underwriters a 30-day option to buy up to an additional 675,000 shares of its common stock.

J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.

BEAM Recent Trade

The share price of BEAM descended by -$0.18 during the exchanging session on 10/01/20 to exchange at $24.44. Beam Therapeutics Inc. stock has an exchanging volume of 2.87 million shares, which is high, contrasted with its 3-months average volume of 593.10K shares. Its market capitalization has now reached to $1.23B.

BEAM Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, BEAM price has dropped by -6.32%. In the course of past three months sees the stock go down around -15.34%, while it has gain 60.16% over the past six months and 30.35% since the start of the year.

BEAM Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 6.0 million. For that equivalent quarter, Beam Therapeutics Inc. posted -$0.69 earnings per share (EPS) which was underneath the consensus estimate of -$0.53 by -$0.16, which represents to a reduction by -30.20%.

BEAM Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Beam Therapeutics Inc. has seen its stock exchanging -21.16% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +30.28% above its three-month low. A more extensive look sees BEAM exchanging -23.14% beneath its 52-week high and 88.00% above from its 52-week low price.

BEAM Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 6.39%, while it has a month to month instability of 7.61%. Ticker has an ATR (Average True Range) of 1.89.

Leave a Comment